A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T cell (CAR-T)Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Study of JNJ-75229414 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Janssen
Enrolling: Male and Female Patients
IRB Number: AAAT7624
U.S. Govt. ID: NCT05022849
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if a new, experimental drug called JNJ-75229414 is safe and useful for treating patients with metastatic castration-resistant prostate cancer. JNJ-75229414 is a Chimeric Antigen Receptor T Cell (CAR-T) cell therapy. This is the first time that JNJ75229414 will be used in humans. In this type of treatment, your white blood cells (which are a part of the immune system) will be genetically modified to become JNJ-75229414 and used to treat your metastatic castration-resistant prostate cancer.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with metastatic CRPC (mCRPC)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator